Drug class

Ophthalmic Antiglaucoma Agents

Ophthalmic antiglaucoma agents are a broad therapeutic class of ocular medications formulated to reduce intraocular pressure and prevent progressive optic nerve damage and vision loss. Read more about Ophthalmic Antiglaucoma Agents

172 drugs in this class 59 manufacturers

Advertisement

Drugs in Ophthalmic Antiglaucoma Agents

Showing 109–117 of 172 drugs

BRIMONIDINE TARTRATE

OPHTHALMIC SYMPATHOLYTIC AGENTS · OCULAR HYPERTENSION ·+1
Pfizer Laboratories

DORZOLAMIDE HCL

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS · OCULAR HYPERTENSION ·+1
Pfizer Laboratories

LATANOPROST

OPHTHALMIC PROSTAGLANDIN AGONISTS · OCULAR HYPERTENSION ·+1
Pfizer Laboratories

PILOCARPINE HCL

PARASYMPATHETIC MIOTICS · OCULAR HYPERTENSION ·+3
Pfizer Laboratories

TIMOLOL

OPHTHALMIC BETA-BLOCKERS · OCULAR HYPERTENSION ·+1
Pfizer Laboratories

TIMOLOL MALEATE

OPHTHALMIC BETA-BLOCKERS · OCULAR HYPERTENSION ·+1
Pfizer Laboratories

TRAVOPROST

OPHTHALMIC PROSTAGLANDIN AGONISTS · OCULAR HYPERTENSION ·+1
Pfizer Laboratories

DORZOLAMIDE HCL

OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS · OCULAR HYPERTENSION ·+1
BIOCON PHARMA I
Filter & compare in the drug finder → Opens the drug finder with Ophthalmic Antiglaucoma Agents preselected. Add indication or manufacturer filters there.

About Ophthalmic Antiglaucoma Agents.

Ophthalmic antiglaucoma agents are a broad therapeutic class of ocular medications formulated to reduce intraocular pressure and prevent progressive optic nerve damage and vision loss.

These agents achieve ocular hypotension primarily by decreasing aqueous humor production, increasing trabecular or uveoscleral outflow, or combining both pathways through mechanisms that include prostaglandin analogues, beta-adrenergic antagonists, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors, and Rho kinase inhibitors.

They serve as the primary pharmacologic therapy for managing open-angle glaucoma, ocular hypertension, and select secondary glaucomas, as well as adjunctive medical stabilization in angle-closure glaucoma.